Eye on Innovation
Regulation & Policy
- DEA Close to Unveiling New Telehealth Regulations for Controlled Substance Prescriptions
- Digital Therapeutics Alliance To Launch Accreditation Program to Help Dtx Products Gain Uptake with Payers
- Otsuka and Click Therapeutics Announce the U.S. Food and Drug Administration (FDA) Clearance of Rejoyn™, the First Prescription Digital Therapeutic Authorized for the Adjunctive Treatment of Major Depressive Disorder (MDD) Symptoms
- Artificial Intelligence’s Role in Reshaping Behavioral Health and Navigation of Legal Risks Ahead
- Telehealth Opioid Treatment: Advancing the US Prevention Strategy
- Where Do We Go from Here on Digital Therapeutics?
- Digital Health Technologies for Remote Data Acquisition in Clinical Investigations
- Health Disparities Research Must Remain Focused on Race and Ethnicity and Socioeconomic Status
- How Are AI Companies Reacting to HHS’ New Transparency Requirements?